CN103384665B - 制备促旋酶和拓扑异构酶抑制剂的方法 - Google Patents
制备促旋酶和拓扑异构酶抑制剂的方法 Download PDFInfo
- Publication number
- CN103384665B CN103384665B CN201280009909.2A CN201280009909A CN103384665B CN 103384665 B CN103384665 B CN 103384665B CN 201280009909 A CN201280009909 A CN 201280009909A CN 103384665 B CN103384665 B CN 103384665B
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- hydroxyl
- offer
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCNC(Nc1nc(cc(c(*)c2C3OCCC3)-c3cnc(C(*)(*)*)nc3)c2[n]1)=O Chemical compound CCNC(Nc1nc(cc(c(*)c2C3OCCC3)-c3cnc(C(*)(*)*)nc3)c2[n]1)=O 0.000 description 11
- SGVVIYYDBMCCDQ-UHFFFAOYSA-N C=[N+](c1ccccc1C1OC=CC1)[O-] Chemical compound C=[N+](c1ccccc1C1OC=CC1)[O-] SGVVIYYDBMCCDQ-UHFFFAOYSA-N 0.000 description 1
- WVZIMGUGIRGTNO-UHFFFAOYSA-N CC(C)(c(nc1)ncc1-c(cc1N)cc(C2C(C3)C3CCC2)c1N)[O]=C Chemical compound CC(C)(c(nc1)ncc1-c(cc1N)cc(C2C(C3)C3CCC2)c1N)[O]=C WVZIMGUGIRGTNO-UHFFFAOYSA-N 0.000 description 1
- JBKQHCAUZJBAND-UHFFFAOYSA-N CC(C)(c1ncc(B2OC(C)(C)C(C)(C)O2)cn1)O Chemical compound CC(C)(c1ncc(B2OC(C)(C)C(C)(C)O2)cn1)O JBKQHCAUZJBAND-UHFFFAOYSA-N 0.000 description 1
- IPPKSNUPXHRCKC-GRKSPCFVSA-N CCC(C(C(C1NCC[C@H]1C)=C1N=C)O)C=C1[N+]([O-])=O Chemical compound CCC(C(C(C1NCC[C@H]1C)=C1N=C)O)C=C1[N+]([O-])=O IPPKSNUPXHRCKC-GRKSPCFVSA-N 0.000 description 1
- AZSZEDLBCUNLLI-GOSISDBHSA-N CCNC(N/C(/C)=N/c(cc(cc1[C@@H]2OCCC2)-c2cnc(C(C)(C)O)nc2)c1N)=O Chemical compound CCNC(N/C(/C)=N/c(cc(cc1[C@@H]2OCCC2)-c2cnc(C(C)(C)O)nc2)c1N)=O AZSZEDLBCUNLLI-GOSISDBHSA-N 0.000 description 1
- CGQGUKARKZMGRW-WEFRXHSZSA-N CCNC(NC(NC1)N/C1=C/C(/c1cnc(C(C)(C)O)nc1)=C\C)=O Chemical compound CCNC(NC(NC1)N/C1=C/C(/c1cnc(C(C)(C)O)nc1)=C\C)=O CGQGUKARKZMGRW-WEFRXHSZSA-N 0.000 description 1
- ZFOMTLZWOVESNW-LJQANCHMSA-N CCNC(NC1=C2Nc3cc(-c4cnc(C(C)(C)O)nc4)cc(C4CCCC4)c3[C@@H]12)=O Chemical compound CCNC(NC1=C2Nc3cc(-c4cnc(C(C)(C)O)nc4)cc(C4CCCC4)c3[C@@H]12)=O ZFOMTLZWOVESNW-LJQANCHMSA-N 0.000 description 1
- RYFYZVJHGOSTNX-UHFFFAOYSA-N CNc1c(C2OCCC2)cccc1 Chemical compound CNc1c(C2OCCC2)cccc1 RYFYZVJHGOSTNX-UHFFFAOYSA-N 0.000 description 1
- XKKAUGJSYBOLGO-UHFFFAOYSA-N Nc(c([N+]([O-])=O)c1)c(C2OCCC2)c(F)c1Br Chemical compound Nc(c([N+]([O-])=O)c1)c(C2OCCC2)c(F)c1Br XKKAUGJSYBOLGO-UHFFFAOYSA-N 0.000 description 1
- BECDWMFRMOFJGS-UHFFFAOYSA-N Nc1c(C2OCCC2)c(F)ccc1 Chemical compound Nc1c(C2OCCC2)c(F)ccc1 BECDWMFRMOFJGS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (24)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161432990P | 2011-01-14 | 2011-01-14 | |
US61/432,990 | 2011-01-14 | ||
PCT/US2012/021281 WO2012097274A1 (en) | 2011-01-14 | 2012-01-13 | Process of making gyrase and topoisomerase iv inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103384665A CN103384665A (zh) | 2013-11-06 |
CN103384665B true CN103384665B (zh) | 2018-01-09 |
Family
ID=45815947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280009909.2A Active CN103384665B (zh) | 2011-01-14 | 2012-01-13 | 制备促旋酶和拓扑异构酶抑制剂的方法 |
Country Status (19)
Country | Link |
---|---|
US (2) | US8471014B2 (zh) |
EP (1) | EP2663556B1 (zh) |
JP (1) | JP6006235B2 (zh) |
KR (1) | KR101882172B1 (zh) |
CN (1) | CN103384665B (zh) |
AR (1) | AR084864A1 (zh) |
AU (1) | AU2012205420B2 (zh) |
BR (1) | BR112013017968B1 (zh) |
CA (1) | CA2824519C (zh) |
ES (1) | ES2526902T3 (zh) |
IL (1) | IL227405B (zh) |
MX (1) | MX355561B (zh) |
NZ (1) | NZ612920A (zh) |
PT (1) | PT2663556E (zh) |
RU (1) | RU2619116C2 (zh) |
SG (1) | SG191945A1 (zh) |
TW (1) | TWI534143B (zh) |
WO (1) | WO2012097274A1 (zh) |
ZA (1) | ZA201305232B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2824519C (en) | 2011-01-14 | 2020-06-16 | Vertex Pharmaceuticals Incorporated | Process of making gyrase and topoisomerase inhibitors |
TWI546298B (zh) * | 2011-01-14 | 2016-08-21 | 維泰克斯製藥公司 | 旋轉酶及拓樸異構酶iv抑制劑 |
BR112013017977A2 (pt) * | 2011-01-14 | 2019-09-24 | Vertex Pharma | formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia |
BR112013017985B1 (pt) * | 2011-01-14 | 2021-06-29 | Spero Therapeutics Inc. | Formas sólidas de inibidor de girase (r)-1-etil-3-[6-flúor-5-[2-(1-hidróxi-1-metil-etil)pirimidin- 5-il]-7-(tetra-hidrofuran-2-il)-1h-benzimidazol-2-il]ureia, seu sal de ácido clorídrico, método de preparação das mesmas e composição farmacêutica que os compreende |
CN103702994B (zh) * | 2011-06-20 | 2016-03-23 | 沃泰克斯药物股份有限公司 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
WO2014015105A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
WO2014014845A1 (en) | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
KR20160115986A (ko) | 2014-02-03 | 2016-10-06 | 스페로 자이레이스, 인크 | 폴리믹신을 포함하는 항균성 조합 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481368A (zh) * | 2000-12-15 | 2004-03-10 | ��̩��˹ҩ��ɷ�����˾ | 促旋酶抑制剂和其用途 |
CN1674898A (zh) * | 2002-06-13 | 2005-09-28 | 沃泰克斯药物股份有限公司 | 作为促旋酶和 /或拓扑异构酶 i v的抑制剂用于治疗细菌感染的 2 -脲基-6-杂芳基-3 h-苯并咪唑-4-羧酸衍生物和相关化合物 |
CN101321744A (zh) * | 2005-11-07 | 2008-12-10 | 沃泰克斯药物股份有限公司 | 作为回旋酶抑制剂的苯并咪唑衍生物 |
US20090325955A1 (en) * | 2003-01-31 | 2009-12-31 | Paul Charifson | Gyrase inhibitors and uses thereof |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2015676A1 (de) | 1970-04-02 | 1971-10-21 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Neue Imine der 2-Formyl-chinoxalindi-N-oxidcarbon-säure-(3) und deren Salze, Verfahren zu ihrer Herstellung und ihre Verwendung als antimikrobielle Mittel |
US4174400A (en) | 1978-09-13 | 1979-11-13 | Merck & Co., Inc. | Anthelmintic benzimidazoles |
US4512998A (en) | 1980-10-20 | 1985-04-23 | Schering Corporation | Anthelmintic benzimidazole carbamates |
CA2028530A1 (en) | 1989-11-21 | 1991-05-22 | Christian Hubschwerlen | Substituted pyrimidobenzimidazole derivatives |
DE19514313A1 (de) | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
US5643935A (en) | 1995-06-07 | 1997-07-01 | The University Of North Carolina At Chapel Hill | Method of combatting infectious diseases using dicationic bis-benzimidazoles |
TW538046B (en) | 1998-01-08 | 2003-06-21 | Hoechst Marion Roussel Inc | Aromatic amides having antiobiotic activities and the preparation processes, intermediates and pharmaceutical composition thereof |
AUPP873799A0 (en) | 1999-02-17 | 1999-03-11 | Fujisawa Pharmaceutical Co., Ltd. | Pyridine compounds |
GB9911594D0 (en) | 1999-05-19 | 1999-07-21 | Smithkline Beecham Plc | Novel compounds |
GB9912413D0 (en) | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
AR042956A1 (es) | 2003-01-31 | 2005-07-13 | Vertex Pharma | Inhibidores de girasa y usos de los mismos |
US7618974B2 (en) | 2003-01-31 | 2009-11-17 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US8404852B2 (en) | 2003-01-31 | 2013-03-26 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US7569591B2 (en) | 2003-01-31 | 2009-08-04 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
US8193352B2 (en) | 2003-01-31 | 2012-06-05 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
RU2328495C2 (ru) * | 2003-03-07 | 2008-07-10 | Кова Ко., Лтд. | Производное бензофурана |
GB0724349D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Antibacterial agents |
US8481544B2 (en) | 2006-06-22 | 2013-07-09 | Biota Europe Limited | Antibacterial compositions |
GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
ES2363178T3 (es) | 2006-12-04 | 2011-07-26 | Astrazeneca Ab | Compuestos de urea policíclicos antibacterianos. |
GB0724342D0 (en) | 2007-12-13 | 2008-01-30 | Prolysis Ltd | Anitbacterial compositions |
EP2321309A1 (en) | 2008-06-25 | 2011-05-18 | Ranbaxy Laboratories Limited | Benzothiazoles and aza-analogues thereof use as antibacterial agents |
WO2011032050A2 (en) | 2009-09-11 | 2011-03-17 | Trius Therapeutics, Inc. | Gyrase inhibitors |
CA2777741A1 (en) | 2009-10-16 | 2011-04-21 | Rib-X Pharmaceuticals, Inc. | Antimicrobial compounds and methods of making and using the same |
CN103249732B (zh) | 2010-10-08 | 2016-08-10 | 生物区欧洲有限公司 | 抑制2-乙基氨甲酰氨基-1,3-苯并噻唑-5-基的细菌拓扑异构酶ii |
TWI546298B (zh) * | 2011-01-14 | 2016-08-21 | 維泰克斯製藥公司 | 旋轉酶及拓樸異構酶iv抑制劑 |
BR112013017985B1 (pt) * | 2011-01-14 | 2021-06-29 | Spero Therapeutics Inc. | Formas sólidas de inibidor de girase (r)-1-etil-3-[6-flúor-5-[2-(1-hidróxi-1-metil-etil)pirimidin- 5-il]-7-(tetra-hidrofuran-2-il)-1h-benzimidazol-2-il]ureia, seu sal de ácido clorídrico, método de preparação das mesmas e composição farmacêutica que os compreende |
BR112013017977A2 (pt) * | 2011-01-14 | 2019-09-24 | Vertex Pharma | formas sólidas de inibidor de girase (r) 1-etil-3-[5-[2-{1-hidroxi-1-metil-etil}pirimidin-5-il]-7-(tetrai-drofuran-2-il)-1h-benzimidazol-2-il]ureia |
CA2824519C (en) | 2011-01-14 | 2020-06-16 | Vertex Pharmaceuticals Incorporated | Process of making gyrase and topoisomerase inhibitors |
CN103702994B (zh) * | 2011-06-20 | 2016-03-23 | 沃泰克斯药物股份有限公司 | 旋转酶和拓扑异构酶抑制剂的磷酸酯 |
JP2015514063A (ja) | 2012-03-22 | 2015-05-18 | ビオタ ヨーロッパ リミテッドBiota Europe Ltd | 抗菌化合物 |
WO2014015105A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of (r)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1h-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof |
WO2014014845A1 (en) * | 2012-07-18 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases |
-
2012
- 2012-01-13 CA CA2824519A patent/CA2824519C/en active Active
- 2012-01-13 US US13/349,884 patent/US8471014B2/en active Active
- 2012-01-13 BR BR112013017968-6A patent/BR112013017968B1/pt active IP Right Grant
- 2012-01-13 AU AU2012205420A patent/AU2012205420B2/en active Active
- 2012-01-13 CN CN201280009909.2A patent/CN103384665B/zh active Active
- 2012-01-13 ES ES12708416.8T patent/ES2526902T3/es active Active
- 2012-01-13 PT PT127084168T patent/PT2663556E/pt unknown
- 2012-01-13 SG SG2013053418A patent/SG191945A1/en unknown
- 2012-01-13 EP EP12708416.8A patent/EP2663556B1/en active Active
- 2012-01-13 KR KR1020137018399A patent/KR101882172B1/ko active IP Right Grant
- 2012-01-13 MX MX2013008164A patent/MX355561B/es active IP Right Grant
- 2012-01-13 RU RU2013137751A patent/RU2619116C2/ru active
- 2012-01-13 TW TW101101505A patent/TWI534143B/zh active
- 2012-01-13 WO PCT/US2012/021281 patent/WO2012097274A1/en active Application Filing
- 2012-01-13 NZ NZ612920A patent/NZ612920A/en unknown
- 2012-01-13 JP JP2013549579A patent/JP6006235B2/ja active Active
- 2012-01-16 AR ARP120100138A patent/AR084864A1/es active IP Right Grant
-
2013
- 2013-05-28 US US13/903,506 patent/US8912326B2/en active Active
- 2013-07-10 IL IL227405A patent/IL227405B/en active IP Right Grant
- 2013-07-11 ZA ZA2013/05232A patent/ZA201305232B/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1481368A (zh) * | 2000-12-15 | 2004-03-10 | ��̩��˹ҩ��ɷ�����˾ | 促旋酶抑制剂和其用途 |
CN1674898A (zh) * | 2002-06-13 | 2005-09-28 | 沃泰克斯药物股份有限公司 | 作为促旋酶和 /或拓扑异构酶 i v的抑制剂用于治疗细菌感染的 2 -脲基-6-杂芳基-3 h-苯并咪唑-4-羧酸衍生物和相关化合物 |
US20090325955A1 (en) * | 2003-01-31 | 2009-12-31 | Paul Charifson | Gyrase inhibitors and uses thereof |
CN101321744A (zh) * | 2005-11-07 | 2008-12-10 | 沃泰克斯药物股份有限公司 | 作为回旋酶抑制剂的苯并咪唑衍生物 |
Non-Patent Citations (2)
Title |
---|
Novel Dual-Targeting Benzimidazole Urea Inhibitors of DNA Gyrase and Topoisomerase IV Possessing Potent Antibacterial Activity: Intelligent Design and Evolution through the Judicious Use of Structure-Guided Design and Stucture-Activity Relationships;Paul S. Charifson,等;《J. Med. Chem.》;20080908;第51卷(第17期);第5249页方案2,第5250页方案4步骤c,第5251页方案8,第5253页方案12 * |
Palladium-Catalyzed Synthesis of trans-2,5-Diaryltetrahydrofurans,Potent Platelet-Activating Factor Antagonists;Richard C. Larock,等;《J. Org. Chem.》;19900131;第55卷(第2期);第408页左栏第1段、实施例3、第407页右栏第2段、实例(2) * |
Also Published As
Publication number | Publication date |
---|---|
AU2012205420A1 (en) | 2013-08-01 |
EP2663556A1 (en) | 2013-11-20 |
RU2013137751A (ru) | 2015-02-20 |
CN103384665A (zh) | 2013-11-06 |
TW201307332A (zh) | 2013-02-16 |
WO2012097274A1 (en) | 2012-07-19 |
IL227405B (en) | 2018-05-31 |
KR101882172B1 (ko) | 2018-07-26 |
KR20140037028A (ko) | 2014-03-26 |
CA2824519C (en) | 2020-06-16 |
AU2012205420B2 (en) | 2016-12-08 |
US20120184742A1 (en) | 2012-07-19 |
JP2014503558A (ja) | 2014-02-13 |
ZA201305232B (en) | 2014-11-26 |
US8912326B2 (en) | 2014-12-16 |
TWI534143B (zh) | 2016-05-21 |
PT2663556E (pt) | 2014-11-27 |
BR112013017968B1 (pt) | 2021-03-16 |
MX2013008164A (es) | 2013-08-27 |
RU2619116C2 (ru) | 2017-05-12 |
MX355561B (es) | 2018-04-23 |
AR084864A1 (es) | 2013-07-10 |
US20130261305A1 (en) | 2013-10-03 |
IL227405A0 (en) | 2013-09-30 |
BR112013017968A2 (pt) | 2016-07-12 |
SG191945A1 (en) | 2013-08-30 |
US8471014B2 (en) | 2013-06-25 |
ES2526902T3 (es) | 2015-01-16 |
JP6006235B2 (ja) | 2016-10-12 |
NZ612920A (en) | 2015-10-30 |
EP2663556B1 (en) | 2014-10-15 |
CA2824519A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103384665B (zh) | 制备促旋酶和拓扑异构酶抑制剂的方法 | |
Ökten et al. | Synthesis, characterization, crystal structures, theoretical calculations and biological evaluations of novel substituted tacrine derivatives as cholinesterase and carbonic anhydrase enzymes inhibitors | |
TWI723047B (zh) | 抗真菌化合物方法 | |
CN107108676A (zh) | 用于制备非对映异构纯的磷酰胺酯前药的方法 | |
KR20050057126A (ko) | 아자-비시클로알킬 에테르 및 이들의 알파7-nAChR 효능제로서의 용도 | |
CN103570725A (zh) | 哌嗪并三唑类化合物及其制备方法和用途 | |
TW200922937A (en) | Process for the synthesis of E1 activating enzyme inhibitors | |
CN101679357A (zh) | 取代的杂环衍生物及其组合物和作为抗菌剂的药物用途 | |
JP2005501021A (ja) | 抗細菌剤 | |
KR20220020916A (ko) | GluN2B 수용체 조절제로서의 피리딘 카르바메이트 및 이들의 용도 | |
MX2013008629A (es) | Inhibidores de histona desacetilasa y composiciones y metodos para su uso. | |
Huang et al. | Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays | |
Ahmed et al. | Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives | |
CN104804001B9 (zh) | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 | |
Xing et al. | Design, synthesis and biological evaluation of anthranilamide derivatives as potential factor Xa (fXa) inhibitors | |
ES2915123B2 (es) | Proceso para la síntesis de la sal sódica del ácido 4-[[(1R)-2-[5-(2-fluoro-3-metoxifenil)-3-[[2-fluoro-6-(trifluorometil)-fenil]metil]-3,6-dihidro-4-metil-2,6-dioxo-1(2H)-pirimidinil]-1-feniletil]amino]-butanoico (sal sódica de Elagolix) y productos intermedios de dicho proceso | |
CN109890823A (zh) | 稠合氮杂环化合物及其作为ampa受体调节剂的用途 | |
CN103237780B (zh) | 核苷类似物或其盐、寡核苷酸类似物、基因表达抑制剂和用于检测基因的核酸探针 | |
Cloudsdale et al. | Design, synthesis and biological evaluation of renin inhibitors guided by simulated annealing of chemical potential simulations | |
CA2933483A1 (en) | Substituted dialkyl(oxido)-.lambda4.-sulfanylidene nicotinamide derivatives as kinase inhibitors | |
Cetina et al. | Synthesis and X‐ray study of the 6‐(N‐pyrrolyl) purine and thymine derivatives of 1‐aminocyclopropane‐1‐carboxylic acid | |
Wagner | Synthesis of nicotine derivatives from natural nicotine, total synthesis of (S)-Brevicolline and advances towards the synthesis of dihydrolycolucine | |
WO2012143526A1 (fr) | 1,2,3-triazoles 1,4-disubstituées, leurs procédés de préparation et leurs utilisations diagnostiques et thérapeutiques | |
WO2003074524A2 (en) | Mappicine analogs, intermediates in the synthesis of mappicine analogs and methods of synthesis of mappicine analogs | |
MXPA00004479A (en) | PYRROLO[3,2-b]PYRIDINE PROCESSES AND INTERMEDIATES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1188790 Country of ref document: HK |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20170111 Address after: Massachusetts USA Applicant after: Sparrow, Tom blowing Address before: Massachusetts USA Applicant before: Vertex Pharmaceuticals Incorporated |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1188790 Country of ref document: HK |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200109 Address after: Massachusetts USA Patentee after: Sparrow therapy Address before: Massachusetts USA Patentee before: Sparrow, Tom blowing |
|
TR01 | Transfer of patent right |